The Next Episode | What 13 Years of DSCSA Teach Us About NDC-12 and Pharmaceutical Interoperability
The Transactions Haven’t Changed. The Network Has. Flying home from the HDA Traceability Seminar last week, I saw some news from Philadelphia that put much of what we had spent the previous few days discussing […]
HDA 2026 Traceability Seminar: From Implementation to Interoperability
What comes next for DSCSA OPERATIONS AND INTEROPERABILITY Thirteen years after DSCSA became law, the industry’s focus is shifting from implementation to sustained operation. At the 2026 HDA Traceability Seminar, discussions increasingly centered on what […]
Supply Chain Security Toolkit Video Modules
Get the tools you need for breaking down the barriers that hold the world back from optimal movement of critical goods and materials. Download the index document to access the video modules listed below that […]
Prevention of Reuse of Genuine Packaging Components for Counterfeit Products
“Prevention of Reuse of Genuine Packaging Components for Counterfeit Products” addresses the growing threat of counterfeit pharmaceutical products entering the legitimate supply chain through the reuse of genuine packaging components. Counterfeiters often retrieve discarded packaging—such […]
Cargo Security Risk Assessment and Planning for Global Operations
This whitepaper provides an overview of industry best practices for developing and implementing an effective conveyance
security program regardless of company size or prior experience with supply chain security issues.
Rx-360 Responding to the Threat of Illicit Medicines: Methodologies for Monitoring, Investigation & Stakeholder Engagement
The distribution and sales of illicit products such as counterfeit, unapproved and diverted medicines are a global concern for pharmaceutical patients, health care professionals, regulators and manufacturers. Counterfeit drugs are not equivalent to the genuine […]
Rx-360 Understanding the Threat of Illicit Medicines: An Overview of Counterfeit, Tampered, Unapproved and Diverted Pharmaceuticals
The distribution and sales of illicit products such as counterfeit, unapproved and diverted medicines are a global concern for pharmaceutical patients, health care professionals, regulators and manufacturers. Counterfeit drugs are not equivalent to the genuine […]
Rx-360 Supply Chain Security White Paper: Incident Management Version 2.0
The threats of intentional adulteration, cargo theft, counterfeiting, illegal diversion, and tampering are a serious problem in our global marketplace; where criminals are profiting by putting unassuming patients at risk. These threats are product integrity […]
Rx-360 Supply Chain Security: Audits and Assessments of Third-Party Warehousing and Distribution Facilities Version 2.0
Pharmaceutical manufacturers and distributors frequently outsource various business functions to organizations that have a specialized expertise. While outsourcing can offer improved efficiency and cost savings, it also creates certain risks to product safety and security […]
Rx-360 Technical Paper on Tamper-Evidence and First Opening Indication
The practice of tampering and re-use of original packaging represents a significant threat in the overall landscape of counterfeit and illicit drugs. A problem, which is growing and threatens the global pharmaceutical supply chain as […]